DADC
NGNE icon

D.A. Davidson & Co’s Neurogene NGNE Stock Holding History

D.A. Davidson & Co’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-625
Closed -$176K – 1136
2018
Q1 		$176K Sell
625
-93
-13% -$25.7K ﹤0.01% 1020
2017
Q4 		$169K Buy
718
+215
+43% +$50.4K ﹤0.01% 1036
2017
Q3 		$142K Buy
503
+33
+7% +$9.47K ﹤0.01% 1049
2017
Q2 		$132K Sell
470
-33
-7% -$9.44K ﹤0.01% 1147
2017
Q1 		$167K Buy
503
+25
+5% +$8.78K ﹤0.01% 1018
2016
Q4 		$157K Buy
478
+403
+537% +$108K ﹤0.01% 1104
2016
Q3 		$20K Hold
75
– – ﹤0.01% 1854
2016
Q2 		$9K Buy
75
+25
+50% +$3.97K ﹤0.01% 1986
2016
Q1 		$8K Buy
+50
New +$9.72K ﹤0.01% 1959

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
UONDDL
University of Notre Dame du Lac South Bend, Indiana $66.8M AUM 43.52% 1-Year Est. Return

D.A. Davidson & Co's NGNE Position: Q2 2018 in Review

D.A. Davidson & Co sold out of Neurogene (NGNE) in Q2 2018, closing a stake of 625 shares — an estimated $176K sold.

D.A. Davidson & Co first reported a position in NGNE in Q1 2016 and held it in 9 quarters. The position peaked at $176K in Q1 2018. 44 funds tracked by Wall St. Rank hold NGNE as of Q2 2018.

  • D.A. Davidson & Co reported no remaining Neurogene position as of Q2 2018 after selling out during the quarter.
  • D.A. Davidson & Co sold 625 Neurogene shares in Q2 2018, an estimated $176K.
  • D.A. Davidson & Co first reported a position in Neurogene in Q1 2016 and held it in 9 quarters.
  • D.A. Davidson & Co's Neurogene position peaked at $176K in Q1 2018.
  • 44 funds tracked by Wall St. Rank held Neurogene as of Q2 2018.

Based on D.A. Davidson & Co's 13F filing for Q2 2018, filed 2 Aug 2018.